Denali Therapeutics

DNLINasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$3.941 B

$24.83 +0.40%

Close of 7 Aug 2026

Revenue

$0.00

#3658 by revenue

Earnings

-$512.5M

Loss-making

Shares outstanding

159,847,403

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#23CRISPR TherapeuticsCRSP$5.17B
#24Adaptive BiotechnologiesADPT$3.98B
#25Denali TherapeuticsDNLI$3.94B
#26Relay TherapeuticsRLAY$3.79B
#27Kodiak SciencesKOD$2.84B

Where these numbers come from

Share counts and financials for Denali Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.